BioCeuticals PEA 100mL Liquid
Dose: BioCeuticals PEA
BioCeuticals PEA is compounded at HealthMasters by Naturopath Kevin Tresize ND after a consultation with the patient or to fill a prescription for that particular patient.
Individual dose will be advised after consultation with HealthMasters Online Naturopath Kevin Tresize ND.
For a consultation with HealthMasters Online Naturopath Kevin Tresize ND contact HealthMasters via email email@example.com or telephone 02 4368 7770.
Features: BioCeuticals PEA
- PEA is an endogenous fatty acid amide analogue of the endocannabinoid anandamine, from the N-acylethanolamines family of lipid mediators.
- BioCeuticals PEA Liquid is micronised to a 20um-25um particle size using laser diffraction.
- Presented in a coconut-derived (MCT) lipid suspension for ease of compounding.
- 2mL contains 300mg PEA.
- Synthesised from palmitic acid from sustainably sourced palm oil, RSPO certified palm oil.
- BioCeuticals PEA Liquid contains 99% pure PEA, which has been confirmed by purity testing.
- PEA is a clinically trialled ingredient.
- Low allergen, clean formula.
- Pleasant natural orange flavour.
Indications: BioMedica PEA
- Carpal tunnel syndrome
- Chemotherapy induced neuropathy
- Chronic Neuropathic Pain
- Colds and Flu symptoms
- Diabetic neuropathy
- Failed back surgery
- Inflammatory Pain
- Neuropathic Pain
- Oncology Pain
- Pelvic Pain
- Post-surgical pain
- Post-surgical pain
Ingredients: BioCeuticals PEA
|Each 2mL of BioCeuticals PEA contains:|
Ingredient Summary: BioCeuticals PEA
Palmitoylethanolamide (PEA) is a crystalline, highly lipophilic N-acylethanolamine (NAE), a class of naturally occurring mediators each composed of a fatty acid and ethanolamine; in turn classed as fatty acid ethanolamines (FAEs).
The endocannabinoind, N-arachidonoylethanolamine (anandamide), and its congeners N-stearoylethanolamine and N-oleoylethanolamine, are also members of this family.
PEA acts as an anandamine analogue. 
Anandamide was first isolated from pig brain and classed as the first endocannabinoid. N-acylethanolamines, such as PEA, do not show ligand activity for cannabinoid receptors, anandamide could be concomitantly produced as a by-product of non-endocannabinoid N-acylethanolamines.
Because PEA is lipophilic and poorly water-soluble, its low dissolution rate in fluids can limit absorption and then, therefore, biological responses.
Thus, the particle size of PEA represents a crucial technology issue.
Available clinical trials have utilised PEA products manufactured using several different types of micronisation processes, yielding varying results.
Laser diffraction ultra-micronisation yields an altered crystalline PEA structure with higher energy content, resulting in superior biological efficacy compared to its native form.
References: BioCeuticals PEA
 Tsuboi K, Uyama T, Okamoto Y, Ueda N. Endocannabinoids and related N-acylethanolamines:biological activities and metabolism. Inflammation and Re-generation. 2018;38:28.
 Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174:11.
 Anaesthesia, Pain and Intensive Care. EDITORIAL VIEW - Glia as a new target for neuropathic pain, clinical proof of concept for palmitoylethanolamide, a glia-modulator. Available at: << https:www.apicareonline.com/editorial-view-glia-as-a-new-target-for-neuropathic-pain-clinical-proof-of-concept-for-palmitoylethanolamide-a-glia-modulator/>> Viewed 17th July 2019
Further Information: BioMedica PEA
Warnings: BioCeuticals PEA
Compounding preparations supplied to an individual only after consultation with a health professional. For a consultation with HealthMasters Online Naturopath Kevin Tresize ND contact HealthMasters via email firstname.lastname@example.org or telephone 02 4368 7770.
Keep out of reach of children.
Do not use if seal on cap is broken.
Contains ethanol 6% v/v as a preservative.
Store below 25oC.
Shake well before use.